Capricor Therapeutics stock climbed substantially in mid-day trading, rising 51.0% after the company disclosed - together with its after-close Q2 2026 earnings release - that the U.S. Food and Drug Administration had communicated a willingness to accept a BLA amendment for deramiocel. The proposed amendment would include 24-month open-label extension data from the HOPE-3 study, the company said.
The regulatory signal was notable given a recent FDA advisory committee vote that opposed approval - nine members voted against and three voted in favor - creating investor concern that a regulatory path might be closed off. The agency's openness to a revised submission represented a meaningful reversal in expectations for some market participants.
Analysts reacted quickly to the development. Cantor Fitzgerald moved its rating on the stock from Neutral to Overweight and lifted its price target to $28 from $3.50, citing the newly identified regulatory pathway as a catalyst for renewed conviction. Oppenheimer reiterated an Outperform rating, calling the stock's prior steep decline an attractive risk-reward entry point.
Scientific validation of the underlying data was strengthened by publication of HOPE-3 Phase 3 results in The Lancet, which reported that deramiocel slowed decline in upper limb function by 54% versus placebo. The peer-reviewed article provided independent confirmation of the trial's design and statistical approach as presented in the company's briefing.
On the balance sheet, Capricor reported approximately $238 million in cash at the end of Q2 2026, which the company said is sufficient to fund at least 12 months of operations. Financial results for the quarter showed a net loss of $0.70 per share, wider than the prior year's $0.57 per share loss, and the company recorded zero revenue as it remains in a pre-commercial development stage.
The rally in Capricor shares occurred in the absence of a broader market tailwind. During the session the S&P 500 slipped 0.2%, the Dow Jones fell 0.3%, and the Nasdaq Composite declined 0.4%, underscoring that the move was driven by company-specific news rather than broader equity markets.
Investors also face a near-term regulatory timeline: the company highlighted a PDUFA action date of August 22, 2026, which, together with the FDA's expressed willingness to accept an amended filing, analyst upgrades, and peer-reviewed Phase 3 data, created a concentrated short-term catalyst that outweighed the disappointing quarterly metrics for many market participants.
Contextual note - The information above reflects the company's disclosure and public analyst actions around the Q2 2026 results and regulatory interactions; it does not add or infer outcomes beyond the stated facts.